TY - JOUR
T1 - The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality
T2 - long-term outcomes from the UK Biobank
AU - Chieng, David
AU - Canovas, Rodrigo
AU - Segan, Louise
AU - Sugumar, Hariharan
AU - Voskoboinik, Aleksandr
AU - Prabhu, Sandeep
AU - Ling, Liang-Han
AU - Lee, Geoffrey
AU - Morton, Joseph B.
AU - Kaye, David M.
AU - Kalman, Jonathan M.
AU - Kistler, Peter M.
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Aims Epidemiological studies report the beneficial effects of habitual coffee consumption on incident arrhythmia, cardiovascular disease (CVD), and mortality. However, the impact of different coffee preparations on cardiovascular outcomes and survival is largely unknown. The aim of this study was to evaluate associations between coffee subtypes on incident outcomes, utilizing the UK Biobank. Methods Coffee subtypes were defined as decaffeinated, ground, and instant, then divided into 0, <1, 1, 2–3, 4–5, and >5 cups/day, and results and compared with non-drinkers. Cardiovascular disease included coronary heart disease, cardiac failure, and ischaemic stroke. Cox regression modelling with hazard ratios (HRs) assessed associations with incident arrhythmia, CVD, and mortality. Outcomes were determined through ICD codes and death records. A total of 449 563 participants (median 58 years, 55.3% females) were followed over 12.5 ± 0.7 years. Ground and instant coffee consumption was associated with a significant reduction in arrhythmia at 1–5 cups/day but not for decaffeinated coffee. The lowest risk was 4–5 cups/day for ground coffee [HR 0.83, confidence interval (CI) 0.76–0.91, P < 0.0001] and 2–3 cups/day for instant coffee (HR 0.88, CI 0.85–0.92, P < 0.0001). All coffee subtypes were associated with a reduction in incident CVD (the lowest risk was 2–3 cups/day for decaffeinated, P = 0.0093; ground, P < 0.0001; and instant coffee, P < 0.0001) vs. non-drinkers. All-cause mortality was significantly reduced for all coffee subtypes, with the greatest risk reduction seen with 2–3 cups/day for decaffeinated (HR 0.86, CI 0.81–0.91, P < 0.0001); ground (HR 0.73, CI 0.69–0.78, P < 0.0001); and instant coffee (HR 0.89, CI 0.86–0.93, P < 0.0001). Conclusion Decaffeinated, ground, and instant coffee, particularly at 2–3 cups/day, were associated with significant reductions in incident CVD and mortality. Ground and instant but not decaffeinated coffee was associated with reduced arrhythmia.
AB - Aims Epidemiological studies report the beneficial effects of habitual coffee consumption on incident arrhythmia, cardiovascular disease (CVD), and mortality. However, the impact of different coffee preparations on cardiovascular outcomes and survival is largely unknown. The aim of this study was to evaluate associations between coffee subtypes on incident outcomes, utilizing the UK Biobank. Methods Coffee subtypes were defined as decaffeinated, ground, and instant, then divided into 0, <1, 1, 2–3, 4–5, and >5 cups/day, and results and compared with non-drinkers. Cardiovascular disease included coronary heart disease, cardiac failure, and ischaemic stroke. Cox regression modelling with hazard ratios (HRs) assessed associations with incident arrhythmia, CVD, and mortality. Outcomes were determined through ICD codes and death records. A total of 449 563 participants (median 58 years, 55.3% females) were followed over 12.5 ± 0.7 years. Ground and instant coffee consumption was associated with a significant reduction in arrhythmia at 1–5 cups/day but not for decaffeinated coffee. The lowest risk was 4–5 cups/day for ground coffee [HR 0.83, confidence interval (CI) 0.76–0.91, P < 0.0001] and 2–3 cups/day for instant coffee (HR 0.88, CI 0.85–0.92, P < 0.0001). All coffee subtypes were associated with a reduction in incident CVD (the lowest risk was 2–3 cups/day for decaffeinated, P = 0.0093; ground, P < 0.0001; and instant coffee, P < 0.0001) vs. non-drinkers. All-cause mortality was significantly reduced for all coffee subtypes, with the greatest risk reduction seen with 2–3 cups/day for decaffeinated (HR 0.86, CI 0.81–0.91, P < 0.0001); ground (HR 0.73, CI 0.69–0.78, P < 0.0001); and instant coffee (HR 0.89, CI 0.86–0.93, P < 0.0001). Conclusion Decaffeinated, ground, and instant coffee, particularly at 2–3 cups/day, were associated with significant reductions in incident CVD and mortality. Ground and instant but not decaffeinated coffee was associated with reduced arrhythmia.
KW - Arrhythmia
KW - Cardiovascular disease
KW - Coffee
KW - Congestive cardiac failure
KW - Coronary heart disease
KW - Decaffeinated
KW - Ground
KW - Instant
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85143644674&partnerID=8YFLogxK
U2 - 10.1093/eurjpc/zwac189
DO - 10.1093/eurjpc/zwac189
M3 - Article
C2 - 36162818
AN - SCOPUS:85143644674
SN - 2047-4873
VL - 29
SP - 2240
EP - 2249
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 17
ER -